Comment: valproate dose effects differ across congenital malformations

Area of Science:

• Teratology
• Pharmacology
• Obstetrics

Background:

• Fetal valproate exposure is linked to the highest risk of congenital malformations among antiepileptic drugs.
• Valproate's teratogenic effects are dose-dependent and associated with specific malformations.

Purpose of the Study:

• To analyze the relationship between valproate dosage and the incidence of specific congenital malformations.
• To assess trends in valproate use and its association with malformations in a large pregnancy registry.

Main Methods:

• Analysis of data from the Australian Pregnancy Registry (1999-2012).
• Inclusion of 1,705 pregnancies, with 436 involving valproate exposure.
• Examination of valproate dosage in relation to specific malformation rates.

Main Results:

• Valproate use and dosage decreased over the last five years of the study period.
• Reduced valproate dosages correlated with lower rates of spina bifida and hypospadias.
• Mean dosages for spina bifida (2,000 mg/d) and hypospadias (2,417 mg/d) were higher than for other malformations (1,083 mg/d).

Conclusions:

• Decreasing valproate dosage may mitigate risks for specific malformations like spina bifida and hypospadias.
• The dose-dependent teratogenic effect of valproate is further supported.
• Further research is needed to understand the varying teratogenic effects of valproate on different malformations.